NanoenTekInc Cash Flow Conversion Efficiency
NanoenTekInc cash flow conversion efficiency. Based on the latest financial reports, NanoenTekInc (039860) has a cash flow conversion efficiency ratio of 0.031x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩2.26 Billion ≈ $1.53 Million USD) by net assets (₩73.19 Billion ≈ $49.60 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of NanoenTekInc (2013–2024)
Cash flow conversion efficiency of NanoenTekInc from 2013 to 2024. This chart illustrates how NanoenTekInc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of NanoenTekInc for real-time trading data and today's change.
NanoenTekInc Cash Flow Conversion Ratio Explained
NanoenTekInc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
NanoenTekInc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NanoenTekInc ranked by their cash flow conversion efficiency. Also see NanoenTekInc market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Enterprise Group Inc
TO:E
|
0.006x |
|
5E Advanced Materials Inc
NASDAQ:FEAM
|
-0.082x |
|
Mobase Electronics Co.Ltd
KQ:012860
|
0.082x |
|
UBcare. Co. Ltd
KQ:032620
|
0.001x |
|
Hana Pharm Co Ltd
KO:293480
|
0.021x |
|
Source Energy Services Ltd
TO:SHLE
|
0.166x |
|
Insight Molecular Diagnostics Inc.
NASDAQ:IMDX
|
0.435x |
|
Patagonia Gold Corp
V:PGDC
|
-0.104x |
Annual Cash Flow Conversion Efficiency for NanoenTekInc (2013–2024)
The table below shows the annual cash flow conversion efficiency of NanoenTekInc from 2013 to 2024. Review cash generation quality of NanoenTekInc to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩73.99 Billion ≈ $50.15 Million |
₩-2.46 Billion ≈ $-1.67 Million |
-0.033x | -175.79% |
| 2023-12-31 | ₩53.59 Billion ≈ $36.32 Million |
₩-645.79 Million ≈ $-437.64K |
-0.012x | -108.64% |
| 2022-12-31 | ₩57.65 Billion ≈ $39.07 Million |
₩8.04 Billion ≈ $5.45 Million |
0.140x | -21.38% |
| 2021-12-31 | ₩52.34 Billion ≈ $35.47 Million |
₩9.29 Billion ≈ $6.30 Million |
0.177x | +41.71% |
| 2020-12-31 | ₩45.49 Billion ≈ $30.83 Million |
₩5.70 Billion ≈ $3.86 Million |
0.125x | +25.86% |
| 2019-12-31 | ₩41.03 Billion ≈ $27.80 Million |
₩4.08 Billion ≈ $2.77 Million |
0.100x | +131.90% |
| 2018-12-31 | ₩35.15 Billion ≈ $23.82 Million |
₩1.51 Billion ≈ $1.02 Million |
0.043x | -40.33% |
| 2017-12-31 | ₩23.73 Billion ≈ $16.08 Million |
₩1.71 Billion ≈ $1.16 Million |
0.072x | +160.86% |
| 2016-12-31 | ₩25.58 Billion ≈ $17.33 Million |
₩-3.02 Billion ≈ $-2.05 Million |
-0.118x | -28.30% |
| 2015-12-31 | ₩38.41 Billion ≈ $26.03 Million |
₩-3.54 Billion ≈ $-2.40 Million |
-0.092x | -100.69% |
| 2014-12-31 | ₩35.50 Billion ≈ $24.06 Million |
₩-1.63 Billion ≈ $-1.10 Million |
-0.046x | -152.33% |
| 2013-12-31 | ₩23.58 Billion ≈ $15.98 Million |
₩2.07 Billion ≈ $1.40 Million |
0.088x | -- |
About NanoenTekInc
NanoEntek, Inc. engages in the research and development, production, and sale of life-science lab equipment, in vitro diagnostic medical devices, point of care diagnostic devices, and related consumables and solutions in Korea and internationally. It provides FREND system, a fluorescence immunoassay analyzer; BUDDI, a rapid diagnostic test analyzer; rapid diagnostic test items; ADAM-rWBC, a resid… Read more